Medtronic CFO: This Is the Best Pipeline We've Ever Had

Marketed as a premium product with a smaller size and extravascular positioning, distinguishing it from competitors.

Expected to be a long-term growth driver with a $300 million market already established and potential for substantial future growth.

Significantly improved momentum in the diabetes business, with strong growth driven by the 780G pump in Europe, now expanding into the U.S. market.

Launching Simplera Sync sensor in Europe, boasting competitive advantages like smaller size, longer wear, and user-friendly features.

Continual focus on innovation with plans for next-gen algorithms, sensors, patch pumps, and a true artificial pancreas in the pipeline.

PulseSelect, a single-shot catheter, is in limited market release, with plans for full global release.

Affera, a focal catheter with mapping technology, set to launch in Europe, expected to address 85% of the market with unique features like dual energy capabilities and all-in-one functionality.

Confidence in the competitive strength of Evolut FX, especially in treating small annular spaces, with anticipation for positive results from upcoming SMART trial data.

Introduction of Evolut FX Plus to address potential drawbacks of stented valves, aiming to enhance competitiveness further.

Hugo surgical robot deployed in four continents with positive feedback from surgeons and health systems on features like open console, mapping, and modular design.

In the United States, obtaining investigational device exemptions) for various surgeries including urology, gynecology, and hernia.

Go-to-market strategy includes flexible financing options to meet customer needs without competing on price, leveraging existing relationships in advanced surgery.

Medtronic is marketing both to healthcare systems and surgeons new to robotic surgery, as well as systems and surgeons that already have a da Vinci system from Intuitive Surgical.